Newsfeeds - Spark Newswire

1 minute read

Global Blood Therapeutics Announces European Commission Has Granted Marketing Authorization For Oxbryta

February 16, 7:07 AM

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the European Commission (EC) has granted Marketing Authorization for

GBT

5 minute read

Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics

By Phil Hall

February 2, 1:27 PM

Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.

AXSM

2 minute read

FDA
News

Global Blood Therapeutics Says Co’s Oxbryta Tablets For Oral Suspension Now Available For Patients With Sickle Cell Disease In U.S.

By Benzinga Newsdesk

January 10, 10:07 AM

Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by the U.S. Food and

GBT

1 minute read

SVB Leerink Maintains Outperform on Global Blood Therapeutics, Lowers Price Target to $53

By Benzinga Newsdesk

December 21, 5:54 AM

SVB Leerink analyst Andrew Berens maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and lowers the price target from $56 to $53.

GBT

1 minute read

FDA Expands Use Of Global Blood’ Sickle Cell Treatment To Kids Aged 4-12 Years

By Vandana Singh

December 20, 6:26 AM

The

GBT

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

December 17, 5:38 PM

AMRX

4 minute read

FDA
News

Global Blood Therapeutics Confirms Earlier Report FDA Approves Supplemental New Drug Application For Expanded Indication Of Oxbryta For Children As Young As 4 Years Of Age With Sickle Cell Disease

By Benzinga Newsdesk

December 17, 3:09 PM

Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of a supplemental New Drug Application (sNDA) for

GBT